Remove Cardiovascular Disease Remove Coronary Artery Disease Remove Plaque
article thumbnail

Trial Results: Low-Dose Colchicine HelpsTreat Cardiovascular Disease

DAIC

mg reduces the risk of major adverse cardiovascular events (MACE) and supports its use in the treatment of cardiovascular disease. mg)has potential to directly reduce inflammation, which plays a substantial role in the formation and progression of atherosclerotic plaque leading to heart disease, said Matthew J.

article thumbnail

Physiology Friday #199: High-Intensity Interval Training Reduces Coronary Artery Plaque

Physiologically Speaking

Exercise prevents and reverses cardiovascular disease, but whether high-intensity exercise training (HIIT) is safe and effective for adults after minimally invasive heart surgery is unknown. Exercise is a wonder drug for cardiovascular disease (CVD) prevention and reversal.

Plaque 119
article thumbnail

Lowering Atherosclerotic Cardiovascular Disease Events by Treating Residual Inflammatory Risk

DAIC

Atherosclerotic cardiovascular disease (ASCVD), caused by plaque buildup in arterial walls, is one of the leading causes of disability and death worldwide.1,2 7 Research has shown inflammation plays a significant role in the development of atherosclerosis and ASCVD,8-10 and even the formation of plaque.11

article thumbnail

Cleerly Raises $106 Million in Series C Extension Funding

DAIC

Cleerly is dedicated to creating a new standard of care for heart disease by using FDA-cleared solutions powered by artificial intelligence. Cleerly’s pioneering approach to advanced cardiovascular imaging, powered by AI-driven analysis, is elevating the field of diagnostic tools for coronary artery disease.

article thumbnail

Trial Results: Low-Dose Colchicine Helps Treat Cardiovascular Disease

DAIC

mg reduces the risk of major adverse cardiovascular events (MACE) and supports its use in the treatment of cardiovascular disease. mg)has potential to directly reduce inflammation, which plays a substantial role in the formation and progression of atherosclerotic plaque leading to heart disease, said Matthew J.

article thumbnail

Interleukin 6 plasma levels are associated with progression of coronary plaques

Open Heart

Background Inflammation plays a pivotal role in atherogenesis and is a causal risk factor for atherosclerotic cardiovascular disease. Non-invasive coronary CT angiography (CCTA) enables evaluation of coronary plaque phenotype. Baseline total plaque volume was 1394 (1036, 1993) mm 3. p=0.018) and a 4.8%

Plaque 52
article thumbnail

Computed tomographic angiography measures of coronary plaque in clinical trials: opportunities and considerations to accelerate drug translation

Frontiers in Cardiovascular Medicine

Atherosclerotic coronary artery disease (CAD) is the causal pathological process driving most major adverse cardiovascular events (MACE) worldwide. The complex development of atherosclerosis manifests as intimal plaque which occurs in the presence or absence of traditional risk factors.

Plaque 59